Long-term outcome of otherwise healthy individuals with incidentally discovered borderline thrombocytopenia

PLoS Medicine

Volumn 3, Issue 3, 2006, Pages 388-394

  Stasi, Roberto ^a   Amadori, Sergio ^b   Osborn, John ^c   Newland, Adrian C ^d   Provan, Drew ^d  

^a REGINA APOSTOLORUM HOSPITAL   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FOLLOW UP; HISTORY; HUMAN; HUMAN EXPERIMENT; IDIOPATHIC DISEASE; INCIDENTAL FINDING; LONG TERM CARE; MALE; NORMAL HUMAN; PROBABILITY; PROSPECTIVE STUDY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; HEALTH; IDIOPATHIC THROMBOCYTOPENIC PURPURA; INCIDENCE; MIDDLE AGED; PROGNOSIS; TIME;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HEALTH; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PLATELET COUNT; PROGNOSIS; PROSPECTIVE STUDIES; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; TIME FACTORS;

EID: 33645356971     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.0030024     Document Type: Article

References (26)

1. Van den Bossche J, Devreese K, Malfait R, Van de Vyvere M, Wauters A, et al. (2002) Reference intervals for a complete blood count determined on different automated haematology analysers: Abx Pentra 120 Retic, Coulter Gen-S, Sysmex SE 9500, Abbott Cell Dyn 4000 and Bayer Advia 120. Clin Chem Lab Med 40: 69-73.
2. Brummitt DR, Barker HF (2000) The determination of a reference range for new platelet parameters produced by the Bayer ADVIA120 full blood count analyser. Clin Lab Haematol 22: 103-107.
3. Giacomini A, Legovini P, Gessoni G, Antico F, Valverde S, et al. (2001) Platelet count and parameters determined by the Bayer ADVIA 120 in reference subjects and patients. Clin Lab Haematol 23: 181-186.
4. Stasi R, Provan D (2004) Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc 79: 504-522.
5. Mackay IR, Rose NR (1998) Autoimmunity yesterday, today and tomorrow. In: Rose NR, Mackay IR, editors. The autoimmune diseases. 3rd edition. San Diego (California): Academic Press. 849-872.
6. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, et al. (2003) Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349: 1526-1533.
7. McClain MT, Arbuckle MR, Heinlen LD, Dennis GJ, Roebuck J, et al. (2004) The prevalence, onset, and clinical significance of antiphospholipid antibodies prior to diagnosis of systemic lupus erythematosus. Arthritis Rheum 50: 1226-1232.
8. Benichou J, Gail MH (1990) Estimates of absolute cause-specific risk in cohort studies. Biometrics 46: 813-826.
9. Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, et al. (2004) A note on competing risks in survival data analysis. Br J Cancer 91: 1229-1235.
10. Buckley MF, James JW, Brown DE, Whyte GS, Dean MG, et al. (2000) A novel approach to the assessment of variations in the human platelet count. Thromb Haemost 83: 480-484.
11. Crawford VL, McNerlan SE, Stout RW (2003) Seasonal changes in platelets, fibrinogen and factor VII in elderly people. Age Ageing 32: 661-665.
12. Peng L, Yang J, Lu X, Okada T, Kondo T, et al. (2004) Effects of biological variations on platelet count in healthy subjects in China. Thromb Haemost 91: 367-372.
13. Chuang-Stein C, Tong DM (1997) The impact and implication of regression to the mean on the design and analysis of medical investigations. Stat Methods Med Res 6: 115-128.
14. Frederiksen H, Schmidt K (1999) The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 94: 909-913.
15. Neylon AJ, Saunders PW, Howard MR, Proctor SJ, Taylor PR (2003) Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: A prospective study of a population-based cohort of 245 patients. Br J Haematol 122: 966-974.
16. Huhn RD, Fogarty PF, Nakamura R, Read EJ, Leitman SF, et al. (2003) High-dose cyclophosphamide with autologous lymphocyte-depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia. Blood 101: 71-77.
17. Jayabose S, Levendoglu-Tugal O, Ozkaynkak MF, Visintainer P, Sandoval C (2004) Long-term outcome of chronic idiopathic thrombocytopenic purpura in children. J Pediatr Hematol Oncol 26: 724-726.
18. Stasi R, Pagano A, Stipa E, Amadori S (2001) Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 98: 952-957.
19. Rajab JA, Muchina WP, Orinda DA, Scott CS (2005) Blood donor haematology parameters in two regions of Kenya. East Afr Med J 82: 123-127.
20. Cheng CK, Chan J, Cembrowski GS, van Assendelft OW (2004) Complete blood count reference interval diagrams derived from NHANES III: Stratification by age, sex, and race. Lab Hematol 10: 42-53.
21. Jacobson DL, Gange SJ, Rose NR, Graham NM (1997) Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin Immunol Immunopathol 84: 223-243.
22. Crabtree GR, Lee JC, Cornwell GG 3rd (1975) Letter: Autoimmune thrombocytopenia purpura and Hashimoto's thyroiditis. Ann Intern Med 83: 371-372.
23. Ringold DA, Nicoloff JT, Kesler M, Davis H, Hamilton A, et al. (2002) Further evidence for a strong genetic influence on the development of autoimmune thyroid disease: The California twin study. Thyroid 12: 647-653.
24. Kim HD, Boggs DR (1979) A syndrome resembling idiopathic thrombocytopenic purpura in 10 patients with diverse forms of cancer. Am J Med 67: 371-377.
25. Schwartz KA, Slichter SJ, Harker LA (1982) Immune-mediated platelet destruction and thrombocytopenia in patients with solid tumours. Br J Haematol 51: 17-24.
26. de Latour RP, Des Guetz G, Laurence V, Palangie T, Pierga JY, et al. (2004) Breast cancer associated with idiopathic thrombocytopenic purpura: a single center series of 10 cases. Am J Clin Oncol 27: 333-336.